Why the study?
What are the therapeutic and toxic plasma digoxin concentrations in patients with atrial fibrillation?
What are the therapeutic and toxic plasma digoxin concentrations in patients with atrial fibrillation?
Plasma digoxin levels help differentiate therapeutic from toxic states in atrial fibrillation, with toxicity unlikely below 2 ng/ml, though resting heart rate correlates poorly with plasma levels.
May inform digoxin monitoring in AF; leaves open prospective validation of toxicity thresholds.
Plasma digoxin concentrations were measured by radioimmunoassay in 116 patients with atrial fibrillation on long-term oral treatment with the drug, and in 23 patients with digoxin toxicity. The mean concentrations were 1.4 ng./ml. and 3.1 ng./ml., respectively. Though an overlap occurred between the therapeutic and toxic ranges, toxicity is unlikely to occur below a level of 2 ng./ml. Plasma concentration showed a poor correlation with resting heart rate during atrial fibrillation. In patients with good renal function, however, a significant correlation was found between oral dose and plasma concentration. No evidence was obtained for increased sensitivity to therapeutic concentrations of the drug in elderly subjects, but the doses required to achieve these concentrations tended to be less than in younger patients.
No takes yet. Share an insight, caveat, or question.
Chamberlain et al. (1970) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: